PriceTargets.com logo

Astellas Pharma - ALPMY Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$14.31 As of 09/21/2023 01:00 AM ET
▼ -0.33 (-2.25%)

This chart shows the closing price for ALPMY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Astellas Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALPMY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALPMY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Astellas Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $14.31.

This chart shows the closing price for ALPMY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 2 contributing investment analysts is to moderate buy stock in Astellas Pharma. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/28/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/25/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/24/2023Jefferies Financial GroupDowngradeBuy ➝ Hold
4/16/2023CitigroupUpgradeNeutral ➝ Buy
8/10/2022CitigroupDowngradeBuy ➝ Neutral
4/12/2022CitigroupInitiated CoverageBuy
2/23/2022Jefferies Financial GroupDowngradeBuy ➝ Hold
6/29/2021Jefferies Financial GroupDowngradeBuy ➝ Hold
5/26/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy
1/23/2020Morgan StanleyInitiated CoverageOverweight
9/24/2019Jefferies Financial GroupInitiated CoverageBuy
11/5/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
(Data available from 9/21/2018 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 5 very negative mentions
Mentions as of
3/25/2023
  • 6 very positive mentions
  • 3 positive mentions
  • 6 negative mentions
  • 2 very negative mentions
Mentions as of
4/24/2023
  • 4 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
Mentions as of
5/24/2023
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2023
  • 8 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/23/2023
  • 8 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2023
  • 5 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
Mentions as of
9/21/2023

Current Sentiment

  • 5 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Astellas Pharma logo
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. The company was founded in 1923 and is headquartered in Tokyo, Japan.
Read More

Today's Range

Now: $14.31
Low: $14.01
High: $14.77

50 Day Range

MA: $14.93
Low: $13.92
High: $15.55

52 Week Range

Now: $14.31
Low: $12.82
High: $16.91

Volume

69,042 shs

Average Volume

97,231 shs

Market Capitalization

$25.90 billion

P/E Ratio

34.90

Dividend Yield

2.06%

Beta

0.54

Frequently Asked Questions

What sell-side analysts currently cover shares of Astellas Pharma?

The following sell-side analysts have issued stock ratings on Astellas Pharma in the last twelve months: Citigroup Inc., and Jefferies Financial Group Inc..
View the latest analyst ratings for ALPMY.

What is the current price target for Astellas Pharma?

0 Wall Street analysts have set twelve-month price targets for Astellas Pharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Astellas Pharma in the next year.
View the latest price targets for ALPMY.

What is the current consensus analyst rating for Astellas Pharma?

Astellas Pharma currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ALPMY.

What other companies compete with Astellas Pharma?

Other companies that are similar to Astellas Pharma include Horizon Therapeutics Public, Genmab A/S, Alnylam Pharmaceuticals, BeiGene and UCB. Learn More about companies similar to Astellas Pharma.

How do I contact Astellas Pharma's investor relations team?

Astellas Pharma's physical mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The company's listed phone number is (133) 244-3000. The official website for Astellas Pharma is www.astellas.com. Learn More about contacing Astellas Pharma investor relations.